(1) Solid-phase radioimmunoassay showed that levels of antibodies to denatured collagen in synovial fluid were significantly higher in RA patients than in OAD patients (median 3,270, range 44-16,816 versus median 919, range 119-5,814; P less than 0.001).
(2) In contrast, MDD in mothers conferred a risk for OAD in younger children and of MDD in older children.
(3) Digital subtraction angiography (DSA) was performed in 31 patients with the open arterial duct (OAD), of them 15 were outpatients.
(4) CR1 and CR3 were found to be present on the majority (> 85%) of circulating neutrophils from normal subjects, RA and OAD patients, and on synovial fluid neutrophils from both patient groups.
(5) Octanamide (OAD) was different from the other four amides investigated, having a high clearance (due to metabolic processes in the blood) and possessing the least anticonvulsant activity.
(6) This peak increases first with the progression of occlusive arterial disease (OAD) followed by a decrease at an advanced stage.
(7) Levels of IgG antibodies to denatured or native human type II collagen, rheumatoid factor, immunoglobulins, and total proteins were assessed in paired samples of serum and synovial fluid from 21 patients with RA and from 14 patients with OAD.
(8) However, other groups have been unable to confirm either the biochemical or behavioral findings of Pycock and associates (Joyce et al., 1983; Oades et al., 1986; Deutch et al., 1990).
(9) There was an inhibitory effect on IL-2 activity in the bioassay of synovial fluid from 16 of the 22 patients with RA and 15 of the 16 with OAD.
(10) The first step in the interaction of OADS with the enzyme was the disruption of enzyme-Schiff base, characterized by the rapid disappearance of absorbance at 425 nm (6.5 X 10(3) M-1 s-1) and CD intensity at 430 nm.
(11) In one patient a contrast medium got from the aorta to the pulmonary artery via the arterial duct indicating OAD incomplete closure.
(12) Diagnosis was made in all primary patients using DSA, indications and contraindications for endovascular occlusion of the OAD were defined.
(13) Differences between a clinical sample of younger (ages 5 to 11) and older (ages 12 to 19) children meeting DSM-III criteria for overanxious disorder (OAD) were examined.
(14) Older children more frequently exhibited a concurrent major depression or simple phobia, whereas younger OAD children more commonly had coexisting separation anxiety or attention deficit disorders.
(15) Any cochlear component of OAD does not appear to affect the function of the outer hair cells sufficiently to modify EOAEs materially.
(16) Mean percentage increases observed were: RA patients: CR1, 16.5% (P < 0.001) and CR3, 28.7% (P < 0.001); and OAD patients: CR1, 4.1% and CR3, 26.9% (P = 0.001).
(17) These observations indicate that the aminooxy compounds that are structural analogues of serine (OADS, AAA, and canaline) formed PLP as an intermediate prior to the formation of oxime, whereas with hydroxylamine such an intermediate could not be detected.
(18) One is an oxidative l-arginine deiminase (OAD) that results in the formation of citrulline and reactive nitrogen intermediates.
(19) Older OAD children reported significantly higher levels of anxiety and depression on self-report measures.
(20) Density dependence of maximal expiratory air flow (DD) has been used in adults as a test of early obstructive airway disease (OAD).
Oaf
Definition:
(n.) Originally, an elf's child; a changeling left by fairies or goblins; hence, a deformed or foolish child; a simpleton; an idiot.
Example Sentences:
(1) Big OAF was converted to little OAF by equilibration in 1 M NaCl or 2 M urea.
(2) Outside, there’s no sign of life except one bearded oaf on a chopper and a kid at the back door, holding a picture of Hot Fuss-era Brandon Flowers , praying for a brief encounter.
(3) The effect of interleukin-1 beta, the major component of osteoclast-activating factor (OAF), on bone formation by fetal rat osteoblast-rich cells was investigated.
(4) Recent studies show that osteoclast activating factor (OAF) is homologous to IL-1B.
(5) The resorption response to OAF also resembles that of PTH in having a steep dose response curve and being only transiently inhibited by calcitonin and partially inhibited by increasing medium phosphate concentration.
(6) Spleen cells treated with mitogens produce a potent bone-resorbing factor called osteoclast-activating factor (OAF).
(7) In contrast, supernatant fluids from concanavalin A (Con-A)-activated murine spleen cell cultures (murine osteoclast-activating factor; OAF) consistently and significantly induced a 3- to 5-fold stimulation of bone resorption in this system.
(8) OAF production is probably related to the nature of hydrocarbons in the air.
(9) Calcium release was significantly increased for all agents between 12 and 24 h. It is concluded that bone resorption by 1,25(OH)2D3, OAF, and PGE2 is mediated primarily by increased activity of existing osteoclasts similar to PTH activation.
(10) The presence of bactericidal compounds (open air factor = OAF) could be demonstrated on several days and quantitated in relative units of OAF concentration.
(11) The current studies were designed to produce monoclonal antibodies against OAF for use in the subsequent design of immunoassays for OAF in clinical samples.
(12) In this study we examined the relationship between the lymphocyte and monocyte in OAF production.
(13) The lymphokine osteoclast-activating factor (OAF) was purified to homogeneity.
(14) These results indicate that prostaglandin synthesis is necessary for OAF production.
(15) Are there really "nine sleeps 'til new Who" you gurgling oaf?
(16) Bones from mi mice showed a generalized resorption defect with decreased spontaneous or control resorption and failure to respond to parathyroid hormone (PTH), prostaglandin E2, 1,25 dihydroxy vitamin D3, vitamin A, or osteoclast activating factor (OAF) from human peripheral leukocytes or mouse spleen cells.
(17) OAF release was stimulated by pokeweed mitogen and concanavalin A as well as by phytohemagglutinin.
(18) When PGE1 and PGE2 (0.1 microM) were added exogenously to the enriched lymphocyte population, OAF release occurred after stimulation with PHA.
(19) We have further characterized osteoclast activating factor (OAF) using a bioassay for bone resorption which utilizes the release of previously incorporated (45)Ca from fetal rat long bones in organ culture.
(20) The demonstration of increased osteoclast activating factor (OAF) derived from the cultured myeloma cells from each case suggests that the secretion of OAF and immunoglobulin are unrelated.